Bayer: two abstracts on Rivaroxaban to come at ESC congress.
(CercleFinance.com) - Bayer and its development partner Janssen Research will present two abstracts featuring new clinical data from a Phase III study on oral anticoagulant Rivaroxaban at the ESC congress.
The German chemicals and drugs group said that the results from the largest clinical study on Rivaroxaban to date will provide new insights into the management of patients with chronic coronary and peripheral artery disease.
For the record, the study was stopped early because of "overwhelming efficacy," with the drug having met its primary endpoint.
The ESC congress will take place in Barcelona, from 26 to 30 August.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The German chemicals and drugs group said that the results from the largest clinical study on Rivaroxaban to date will provide new insights into the management of patients with chronic coronary and peripheral artery disease.
For the record, the study was stopped early because of "overwhelming efficacy," with the drug having met its primary endpoint.
The ESC congress will take place in Barcelona, from 26 to 30 August.
Copyright (c) 2017 CercleFinance.com. All rights reserved.